Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003555 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00003555 is a Phase 1 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 20 participants.
The verdict
NCT00003555, a Phase 1 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of paclitaxel plus chemoprotection with amifostine in treating patients with recurrent or refractory solid tumors.
Interventions
- DRUG paclitaxel
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1998-07 |
| Est. Completion | 2003-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003555
The ClinicalTrials.gov registry entry for NCT00003555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00003555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003555 about?
NCT00003555 is a clinical study titled "Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of paclitaxel plus che...
What is the current status of trial NCT00003555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 1998-07. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00003555?
The interventions under investigation include: paclitaxel (DRUG), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003555?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.